H.R. 1092 · 118th Congress (2023–2025)
BENEFIT Act of 2023
This bill requires the Food and Drug Administration (FDA) to consider relevant patient experience data in the risk-benefit assessment framework used in the process for approving new drugs.
After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.
Show official title
To strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 1092’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Doris O. Matsui (D-CA-7)
- Cosponsors
31 cosponsors
1 original · 30 later
16 R · 15 D
- Rep. Brad R. Wenstrup (R-OH-2)· Original · Feb 17, 2023
- Rep. Gus M. Bilirakis (R-FL-12)· Later · Mar 21, 2023
- Rep. Chellie Pingree (D-ME-1)· Later · Apr 10, 2023
- Rep. Rudy Yakym III (R-IN-2)· Later · Apr 10, 2023
- Rep. Mark E. Green (R-TN-7)· Later · Apr 13, 2023
- Rep. Deborah K. Ross (D-NC-2)· Later · Apr 18, 2023
- Rep. Tim Burchett (R-TN-2)· Later · Apr 19, 2023
- Rep. Jared F. Golden (D-ME-2)· Later · May 2, 2023
- Rep. Don Bacon (R-NE-2)· Later · Sep 8, 2023
- Rep. Emanuel Cleaver (D-MO-5)· Later · Sep 8, 2023
- Rep. Susan Wild (D-PA-7)· Later · Sep 8, 2023
- Rep. Tony Cárdenas (D-CA-29)· Later · Sep 26, 2023
- Rep. Brian K. Fitzpatrick (R-PA-1)· Later · Sep 26, 2023
- Rep. Josh Harder (D-CA-9)· Later · Sep 26, 2023
- Rep. Brian Higgins (D-NY-26)· Later · Oct 10, 2023
- Del. Eleanor Holmes Norton (D-DC)· Later · Oct 10, 2023
- Rep. Shri Thanedar (D-MI-13)· Later · Oct 10, 2023
- Rep. Dean Phillips (D-MN-3)· Later · Oct 12, 2023
- Rep. Tom Cole (R-OK-4)· Later · Oct 18, 2023
- Rep. Josh Gottheimer (D-NJ-5)· Later · Oct 30, 2023
- Rep. Jefferson Van Drew (R-NJ-2)· Later · Dec 5, 2023
- Res. Comm. Jenniffer González-Colón (R-PR)· Later · Dec 22, 2023
- Rep. Doug LaMalfa (R-CA-1)· Later · Jan 29, 2024
- Rep. Michael Lawler (R-NY-17)· Later · Mar 7, 2024
- Rep. John James (R-MI-10)· Later · Mar 19, 2024
- Rep. Glenn Thompson (R-PA-15)· Later · Mar 19, 2024
- Rep. Debbie Wasserman Schultz (D-FL-25)· Later · May 21, 2024
- Rep. Paul Tonko (D-NY-20)· Later · May 22, 2024
- Rep. Greg Landsman (D-OH-1)· Later · Jun 7, 2024
- Rep. Troy Balderson (R-OH-12)· Later · Jun 26, 2024
- Rep. Glenn Grothman (R-WI-6)· Later · Sep 25, 2024
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · Feb 17, 2023 – Feb 24, 2023
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Feb 29, 2024 · Hearing
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (3)
BENEFIT Act of 2023
Display title, Short title · Introduced in House
Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023
Short title · Introduced in House
To strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.
Official title · Introduced in House